The results found a median CNS-PFS of 5.2 months and median OS of 13.2 months, concluding that intrathecal Trastuzumab can be a promising treatment option for HER2-positive breast cancer patients with LM [39]. This evidence concerns the gene ERBB2 and breast carcinoma.